BIOPOR Share Price | Bioporto A/S Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Bioporto A/S with Similar Stocks

ChemoMetec A/S Embla Medical hf Ambu A/S

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

DKK 446 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.94

Return on Equity

-246.71%

Price to Book

12.67

Revenue and Profits:

Net Sales:

12 Million

(Quarterly Results - Dec 2025)

Net Profit:

-13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.87%

6 Months

-34.9%

1 Year

-38.81%

2 Years

-34.51%

3 Years

-50.51%

4 Years

-42.05%

5 Years

-82.7%

Bioporto A/S for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

10.39%

EBIT Growth (5y)

-9.78%

EBIT to Interest (avg)

-48.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.71

Sales to Capital Employed (avg)

0.36

Tax Ratio

8.84%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

12.47

EV to EBIT

-4.44

EV to EBITDA

-4.56

EV to Capital Employed

37.73

EV to Sales

11.34

PEG Ratio

Dividend Yield

ROCE (Latest)

-850.10%

ROE (Latest)

-246.71%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 46.84% vs 19.70% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 26.11% vs -63.64% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.60",
          "val2": "7.90",
          "chgp": "46.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.40",
          "val2": "-20.70",
          "chgp": "35.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.30",
          "val2": "-18.00",
          "chgp": "26.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,204.00%",
          "val2": "-2,694.10%",
          "chgp": "149.01%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 11.33% vs 16.77% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -20.38% vs -21.14% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "40.30",
          "val2": "36.20",
          "chgp": "11.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.50",
          "val2": "-73.10",
          "chgp": "103.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.80",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-82.10",
          "val2": "-68.20",
          "chgp": "-20.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-2,081.80%",
          "chgp": "208.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

11.60

7.90

46.84%

Operating Profit (PBDIT) excl Other Income

-13.40

-20.70

35.27%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-13.30

-18.00

26.11%

Operating Profit Margin (Excl OI)

-1,204.00%

-2,694.10%

149.01%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 46.84% vs 19.70% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 26.11% vs -63.64% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

40.30

36.20

11.33%

Operating Profit (PBDIT) excl Other Income

2.50

-73.10

103.42%

Interest

0.00

0.80

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-82.10

-68.20

-20.38%

Operating Profit Margin (Excl OI)

0.00%

-2,081.80%

208.18%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 11.33% vs 16.77% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -20.38% vs -21.14% in Dec 2024

All Annual Results

Company CV

About Bioporto A/S

Bioporto A/S

Pharmaceuticals & Biotechnology

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Company Coordinates

Company Details

Tuborg Havnevej 15, St. , HELLERUP None : 2900

Tel: 45 45 29000045 4529 0034

http://www.bioporto.com/

Registrar Details